Tarsus Pharmaceuticals (TARS) IPO Opens Modestly Higher

Today's IPO for Tarsus Pharmaceuticals, Inc., (NASDAQ: TARS) opened for trading at $16.40 after pricing 5,500,000 shares of common stock at a public offering price of $16.00 per share.

In addition, Tarsus has granted the underwriters an option for a period of 30 days to purchase up to 825,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares are being offered and sold by Tarsus.

BofA Securities, Jefferies and Raymond James are acting as joint book-running managers for the offering. LifeSci Capital and Ladenburg Thalmann are acting as co-managers for the offering.

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.

You May Also Be Interested In

• Spacex Shares Indicated To Open At $168.25 Each
• Nasdaq Anticipates SpaceX IPO To Open For Trading Shortly - Bloomberg
• Nasdaq: IPO Of SpaceX To Be Released For Quotation At 9:50am ET